All In Biotech

Drug Trial Radar · NCT04993352

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

A Phase I/II, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of HLX04-O Administered by Intravitreal Injection in Subjects With Wet Age Related Macular Degeneration (wAMD)

Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jul 15, 2021

Primary completion

Jul 7, 2022

Study completion Mar 13, 2023

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HLX04-O administered every 4 weeks in participants with wet age-related macular degeneration (wAMD)

Conditions

  • Age Related Macular Degeneration

Interventions

  • recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injectionDrug

    0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Safety eventsTime frame: week 4
  2. Phase 2: Mean change of letters from baseline in the BCVA at Week 12Time frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • XuZhou Central Hospital

    Xuzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.